Related Experiment Video

Updated: Aug 11, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Mutational analysis of the CDKN2 (MTS1/p16ink4A) gene in primary B-cell lymphomas

T Uchida1, T Watanabe, T Kinoshita

  • 1First Department of Internal Medicine, Nagoya University School of Medicine, Japan.

Blood
|October 1, 1995
PubMed

Insights

Alterations in the CDKN2 gene were found in 14.3% of B-cell non-Hodgkin

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • The CDKN2 gene, encoding the cyclin-dependent kinase-4 inhibitor p16, is frequently altered in tumor cell lines, suggesting a tumor-suppressor role.
  • Understanding CDKN2 gene alterations is crucial for investigating the molecular mechanisms underlying B-cell malignancies.

Purpose of the Study:

  • To evaluate alterations of the CDKN2 gene in primary B-cell non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) specimens.
  • To determine the frequency and types of CDKN2 gene alterations in these hematological malignancies.

Main Methods:

  • Analysis of 52 primary B-cell NHL and CLL specimens.
  • Utilized Southern blot analysis, polymerase chain reaction-mediated single-strand conformation polymorphism (PCR-SSCP), and direct sequencing to detect CDKN2 alterations.

Main Results:

  • Homozygous deletion of CDKN2 was observed in 7.1% (3/42) of B-NHL patients.
  • Identified one missense mutation and two frameshift mutations (due to a 35-bp deletion) in 7.1% (3/42) of B-NHL patients.
  • Overall, CDKN2 alterations were detected in 14.3% (6/42) of B-NHL patients, with no alterations found in 10 B-CLL patients.

Conclusions:

  • CDKN2 gene alterations, including deletions and mutations, are present in a subset of B-cell non-Hodgkin's lymphoma.
  • These findings suggest that CDKN2 alterations play a role in the tumorigenesis of some B-NHL cases.

More Related Videos

Comparative Lesions Analysis Through a Targeted Sequencing Approach08:16

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor09:33

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor

Published on: August 25, 2023

Related Concept Videos

Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...